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Background: Reduction in the prevalence of vaccine type HPV infection in young women is an early
indication of the impact of theHPV immunisation programme and a necessary outcome if the subsequent
impact on cervical cancer is to be realised.
Methods: Residual vulva-vaginal swab (VVS) specimens from young women aged 16–24 years under-
going chlamydia screening in community sexual health services (formerly known as family planning
clinics), general practice (GP), and youth clinics in 2010–2012 were submitted from 10 laboratories in
seven regions around England. These specimens were linked to demographic and sexual behaviour data
reported with the chlamydia test, anonymised, and tested for type-speciﬁc HPV DNA using a multiplex
PCR and Luminex-based genotyping test. Estimated immunisation coverage was calculated and ﬁndings
were compared to a baseline survey conducted prior to the introduction of HPV immunisation in 2008.
Results: A total of 4664 eligible specimens were collected and 4178 had a valid test result. The post-
immunisation prevalence of HPV 16/18 infection was lowest in this youngest age group (16–18 years)
and increasedwithage. This increasewithagewasa reversal of thepatternseenprior to immunisationand
was inversely associatedwith estimates of age-speciﬁc immunisation coverage (65% for 16–18 year olds).
The prevalence of HPV 16/18 infection in the post-immunisation survey was 6.5% amongst 16–18 year
olds, compared to 19.1% in the similar survey conducted prior to the introduction of HPV immunisation.
Conclusions: These ﬁndings are the ﬁrst indication that the national HPV immunisation programme is
successfully preventing HPV 16/18 infection in sexually active young women in England. The reductions
seen suggest, for the estimated coverage, high vaccine effectiveness and some herd-protection beneﬁts.
Continued surveillance is needed to determine the effects of immunisation on non-vaccine HPV types.
Crown Copyright © 2013 Published by Elsevier Ltd.
1. Introduction
Clinical trials have shown human papillomavirus (HPV) pro-
phylactic vaccines to have high efﬁcacy against cervical HPV
infection and HPV-related cervical disease associated with the
Abbreviations: CI, Conﬁdence Interval;GP,General Practice;HC2,HybridCapture
2; HPV, Human Papillomavirus; HR, High-risk; LA, Linear Array; LR, Low-risk; LSOA,
Lower Super Output Area; NCSP, National Chlamydia Screening Programme; OR,
Odds ratio; PCR, Polymerase Chain Reaction; PCT, Primary Care Trust; PDH, Pyruvate
dehydrogenase; PHE, Public Health England; REC, Research Ethics Committee; VVS,
Vulva-vaginal Swab.
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vaccine HPV types [1–3] and HPV immunisation programmes have
been introduced in many countries [4]. In England, the national
HPV immunisation programme began in September 2008, using
the bivalent HPV 16/18 vaccine (Cervarix®). Routine vaccination is
offered, in schools (with few exceptions), to girls aged 12 years at
the start of each academic year (September). Catch-up immunisa-
tion was provided, in schools and by general practitioners (mostly
for the oldest cohorts), to girls who were aged 13–17 years when
the programme began (September 2008). Vaccine uptake has been
high with coverage of over 80% of 12 year olds for all three vaccine
doses. Coverage amongst the catch-up cohorts was lower and var-
ied by age at vaccination (overall 56% for three doses; range 39%
to 76%) [5]. The programme changed to use the quadrivalent HPV
6/11/16/18 vaccine (Gardasil®) for routine immunisation of 12 year
olds in September 2012.
In England, women are invited for cervical screening from 25
years of age: hence the earliest we expect to see any effect of vacci-
nation on the incidence of cervical abnormalities is 2015, and girls
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immunised aged 12 years will not be invited for screening until
2020. Tomonitor the impact of the immunisation programmeprior
to impact on disease,we are conducting surveillance of vaccine and
non-vaccineHPVtype infectionsamongst specimensobtained from
sexually active young (16–24 years) females undergoing oppor-
tunistic screening for Chlamydia trachomatis as part of the English
National Chlamydia Screening Programme (NCSP) [6]. Chlamydia
screening is recommended for all sexually active young women,
annually and on partner change, and is offered opportunistically
when they attend a range of services [6]. An HPV survey was ﬁrst
done in 2008. This analysis explores the prevalence of HPV16/18
within 3 years of startingwide-spread immunisation and compares
this to pre-immunisation ﬁndings from 2008 [7]. The prevalence of
other HR types is also reported.
2. Methods
2.1. Sample and data collection
Residual vulva-vaginal swab (VVS) specimens submitted for
chlamydia screening from community sexual health services (for-
merly known as family planning clinics), general practice (GP),
and youth clinics were collected from 10 laboratories (six serv-
ing largely urban populations and four serving more rural areas)
in seven regions around England. These laboratorieswere recruited
based on their throughput of eligible specimens (at least 700during
a6monthperiod), anddistribution throughout England. Specimens
collected between October 2010 and end of June 2012 and tested
by September 2012 were included in this analysis.
Procedures for specimen and data collection have been
described previously for the pre-immunisation survey conducted
in 2008 [7]. In brief, residual chlamydia screening specimens were
sent to Public Health England (PHE) labelled with a unique study
number. A temporary list of identiﬁers enabled matching to data
reported separately toPHE for the chlamydia screen (age, date spec-
imen collection, lower layer super output area (LSOA) of residence,
screening venue of specimen collection, ethnicity, two ormore sex-
ual partners in the previous 12 months, new sexual partner in past
3 months, chlamydia screen result). All personal identiﬁers were
then irreversiblydeletedprior to release forHPV testing. Specimens
that could not be linked to reported data were excluded, as were
any specimens matched to data indicating that they did not meet
the inclusion criteria. HPV immunisation status for each subject
was not available for this analysis: coveragewithin each age-group
was estimated by combining published data for each birth-cohort
by year [5]. Coverage estimates generated using the national cover-
age data and using coverage data only from the relevant local areas
(i.e. the PCTs of our subjects’ places of residence) were similar: the
national data were used.
This unlinked anonymous surveymethodology, conductingHPV
testing without seeking speciﬁc consent from subjects, was given a
favourable ethical opinion by South East Research Ethics Commit-
tee (REC reference number 10/H1102/7).
2.2. HPV testing
The collected, eligible, VVS specimens were tested for
type-speciﬁc HPV DNA using an in-house multiplex PCR and
Luminex-based genotyping test [8]. This test detects the 13 high-
risk types (HR) classiﬁed by the International Agency for Research
on Cancer 2009 as at least ‘probably’ carcinogenic in the human
cervix (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), ﬁve
possible HR types (HPV 26, 53, 70, 73 and 82), and two low-risk
(LR) types (HPV 6 and 11) [9]. Specimens were deemed inadequate
if they were negative for both HPV and the housekeeping gene,
pyruvate dehydrogenase (PDH).
Specimens collected in 2008 had been tested using the Hybrid
Capture 2 HPV DNA test (HC2; originally developed by the Digene
Corporation, now marketed by Qiagen) using the Combined Probe
Cocktail Method to detect probable HR types (as above) and ﬁve LR
types (6, 11, 42, 43and44).HC2positive specimensweregenotyped
using the Linear Array HPV Genotyping (LA) test (Roche Molecu-
lar Systems). Although all HR HPV types detectable by the HC2/LA
algorithm were also detectable using our in-house test, detection
ratesmay be expected to differ between tests. This potential source
of bias in our ﬁndings on comparison with the pre-immunisation
datawas informed by the re-testing of a panel (N=428) of HC2 pos-
itive and negative specimens from the pre-immunisation (2008)
survey with the in-house Luminex-based test. This showed the
post-immunisation test generatedmore HR HPV positives than the
HC2/LA testing algorithm, likely due to the reduced sensitivity of
the HC2 test compared to a PCR ampliﬁcation based system [10].
However, there was close agreement between the two approaches
for detection ofHPV16/18 (positivity of 23.8%by the inhouse geno-
typing test vs. 22.2% by HC2/LA, kappa 0.809), and HPV 31/33/45
(11.2% vs. 11.4%, kappa 0.756). Difference in detection of non-
vaccine HR HPV was greater (27.8% vs. 23.6%, kappa 0.768) and
may be important for interpretation of prevalence differences.
2.3. Data analysis
We compared reported characteristics of subjects in the post-
immunisation period to those of subjects in the pre-immunisation
period to investigate any differences associated with HPV preva-
lence. Several sub-analyses were conducted to check that key
ﬁndings were not sensitive to potential biases due to differences in
the selection of specimens collected pre- and post-immunisation.
Data were weighted so that each laboratory contributed equally to
the analysis, rather than in proportion to the number of specimens
submitted (as in the pre-immunisation survey).
Prevalence estimates were calculated for the following out-
comes: (i) vaccine-type HPV (16/18) (ii) non-vaccine HR HPV, (iii)
any HR HPV and (iv) HR types for which cross-protection has been
reported. Conﬁdence intervals (95%CI)were calculatedusing a logit
transformation.
Logistic regression was used to explore the association of
HPV prevalence with the period of collection (i.e. a binary vari-
able classiﬁed as pre or post the start of the HPV immunisation
programme), adjusting for age, submitting laboratory, chlamy-
dia screening venue, ethnicity, sexual behaviour and chlamydia
infection. The association was expressed as odds ratios (ORs) and
conﬁdence intervals (95% CI) calculated using linearised standard
errors to show statistical signiﬁcance.
Data analyses were conducted using Stata v12.
3. Results
3.1. Study population
Of 4664 VVS specimens tested for type-speciﬁc HPV DNA, 4178
(90%) had a valid result andwere included in the analysis: 234 from
2010, 2691 from 2011 and 1253 from 2012 (Fig. 1).
The source and reported demographic and sexual behaviour
data for these specimens are shown in Table 1, alongside the data
for the pre-immunisation (baseline) specimens. The mean age of
subjects in the post-immunisation surveywas 19.3 years (Standard
deviation (SD) 2.1 years), similar to the pre-immunisation survey
(19.2 years, SD 2.4 years). There were fewer specimens from com-
munity sexual health services in the post-immunisation period
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4664 VVS tested at HPA Virus Reference  Department
4178 valid HPV test result
Reasons for no valid result*: 486
Inadequate result: 244
Insufficient sample: 232
Invalid result: 10
Eligible for vaccination at    
12-13 years (Routine)
n=94
Eligible for vaccination at    
14-16 years (Catch-up)
n=903
Eligible for vaccination at    
16-18 years (Catch-up)
n=1898
Not eligible for vaccine
n=1283
Fig. 1. Flow chart of specimen collection and testing and immunisation categories.
* Inadequate result: the sample is HPV and housekeeping gene (PDH) negative; Insufﬁcient result: not sufﬁcient sample to be tested; Invalid result: other technical reason.
(3.1% vs. 24.0% pre-immunisation), which was the venue with the
highest HR HPV prevalence in 2008 (with relatively more from
youth clinics post-immunisation). The proportion of women with
missing information on sexual behaviour increased between the
two surveys but there was no change in the reported data with
around half of respondents reporting two or more sexual partners
in the previous year and a new sexual partner in the previous 3
months. The specimens were broadly representative, in terms of
Table 1
Characteristics of women included in the pre- and post-immunisation surveys.
Pre-immunisation (2008) Post-immunisation (2010–2011)
Data completeness (%) N (%) Data completeness (%) N (%)
Region of specimen collection (laboratory) 100 100
North West (Aintreea) 472 (19.9) 225 (5.4)
Yorkshire and The Humber (Leedsb) – 941 (22.5)
West Midlands (Stokec) 261 (11.0) 311 (7.4)
East of England (Norfolk and Norwichd) 767 (32.4) 271 (6.5)
East of England (Cambridgee) – 312 (7.5)
South East (East Kentf) – 693 (16.6)
South East (Portsmouthg) – 56 (1.3)
South West (Cornwallh) 478 (20.2) 491 (11.8)
London (University College Londoni) 391 (16.5) 475 (11.4)
London (Lewishamj) – 403 (9.6)
Age–years 100 100
16–18 years 1054 (44.5) 1540 (36.9)
19–21 years 809 (34.1) 1974 (47.2)
22–24 years 506 (21.4) 664 (15.9)
Ethnicity 88 76
White 1936 (92.6) 2552 (80.1)
Black 95 (4.5) 405 (12.7)
Asian 25 (1.2) 86 (2.7)
Other 34 (1.6) 145 (4.5)
Chlamydia screening venue 100 100
General practice 611 (25.8) 1102 (26 4)
Youth clinic 1190 (50.2) 2948 (70.6)
Family planning (Community Sexual Health Services) 568 (24.0) 128 (3.1%)
Two or more sexual partners in the previous 12 months 81 1030 (53.5) 42 881 (50.1)
New sexual partner in the previous 3 months 81 926 (48.2) 44 853 (46.9)
Chlamydia positivity 99 210 (9.0) 99.9 410 (9.8)
Chlamydia positivity (excluding Leeds & Lewisham) NA NA 99.8 133 (4.7)
a Microbiology Laboratory, University Hospital Aintree.
b Microbiology Department, Leeds Teaching Hospitals.
c Central Pathology Laboratory, University Hospital of North Staffordshire.
d Department of Microbiology, Norfolk and Norwich University Hospital.
e Clinical Microbiology and Public Health laboratory, Addenbrooke’s Hospital.
f Virology Department, East Kent Hospitals University.
g Department of Clinical Microbiology, Queen Alexandra Hospital.
h Department of Microbiology, Royal Cornwall Hospital.
i University College London Hospital.
j Department of Microbiology, University Hospital Lewisham.
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Fig. 2. Prevalence of vaccine HPV types (16/18) by age-group and survey period.
* Vaccine coverage estimated using published data on national HPV coverage for
each birth-cohort by year. In the 19–21 year old age-group this is calculated sep-
arately for those women who would have been offered the vaccine as part of the
national HPV immunisation programme.
reported sexual behaviour data, of all chlamydia screens reported
to PHE for females at the selected venues. Relatively high chlamy-
dia positivity was seen amongst specimens from two laboratories
(Leeds 26.4%, Lewisham 7.2%, vs. 4.7% at all other laboratories com-
bined) but no reason could be identiﬁed for systematic selection
bias.
The estimated HPV vaccine coverage was 65% for subjects aged
16–18 years, 30% for those 19–21 years and 0% for those 22–24
years.
3.2. HPV 16/18 prevalence
The prevalence of HPV 16 and/or 18 in the post-immunisation
survey was lowest in 16–18 year olds, at 6.5% (95% CI: 5.2–8.0%)
(Fig. 2). Prevalence increased with age to 12.5% in 19–21 year olds
and18.6% in22–24year olds (p-value for trend<0.0001). In contrast
in 2008, the prevalence was highest in 16–18 year olds (19.1%, 95%
CI: 16.6–21.8%) and lower at older ages (14.8%, 95% CI: 11.9–18.3%
in 22–24 year olds).
The 19–21 year olds in the post-immunisation survey
(2010–2012) included females eligible and not eligible for
immunisation: both these groups had lower HPV prevalence than
found pre-immunisation. Females who were in birth-cohorts eli-
gible for vaccination had a lower prevalence of HPV 16/18 (10.9%
[95% CI: 9.2–12.9%]) than those who were not eligible for vacci-
nation (15.3% [95% CI: 11.7–19.7%]), p-value =0.036. There was no
sign of any reduction amongst females aged 22–24 years.
Therewere signiﬁcant differences in the reductionof prevalence
for different ethnic groups; among white women the prevalence
of HPV 16/18 infection in 16–18 year olds reduced from 19.7% to
6.7% (66%) in pre- vs. post-immunisation surveyswhereas for black
women this reduction was less marked (and not signiﬁcant) from
14.9% to 9.4% (37%). There were too few individuals of Asian and
other ethnic origin for formal comparison.
The adjusted odds ratio for HPV 16/18 infection comparing
the post-immunisation period with the pre-immunisation was
0.3 (95%CI: 0.2–0.5) for 16–18 year olds and increased with age
(Table 2) as would be expected as a reﬂection of vaccine coverage
and age of immunisation (p-value for heterogeneity <0.0001).
3.3. Sub-analysis
Four sub-analyses were conducted: (i) excluding the Leeds and
Lewisham specimens, (ii) restricted to laboratories participating in
both periods, (iii) by chlamydia status and (iv) by venue of chlamy-
dia screening.
HPV16/18 prevalence pre- and post-immunisation among
16–18 year olds was (i) 19.1% vs. 6.2% (68% reduction) (ii) 19.1%
vs. 7.4% (61% reduction), (iii) 38.6% vs. 13.8% in chlamydia positives
(64% reduction) and 16.7% vs. 5.9% in chlamydia negatives (65%
reduction), and (iv) 19.7% vs. 4.8% in the GP clinics (76% reduction),
18.4% vs. 6.7% in community sexual health services (64% reduction)
and 19.6% vs. 8.9% in Youth clinics (55% reduction), respectively.
3.4. HR HPV prevalence
The detected prevalence of non-vaccine HR HPV types was
slightly higher in the post-immunisation period than pre-
immunisation for each age group (Fig. 3). Therewas no clear change
in the pattern of age-speciﬁc prevalence, nor trend in the adjusted
odds ratio by age group (Table 2). These increases combined with
the decreases in HPV 16/18 resulted in similar prevalence of all
HR HPV (i.e. vaccine and non-vaccine types) among 16–18 year
Table 2
Prevalence and odds ratio of HPV infection in the post-immunisation period compared to pre-immunisation, by age group.
Pre-immunisation:
N (%)*
Post-immunisation:
N (%)*
OR (95% CI) Adjusted OR**
(95% CI)
16–18 years
HPV 16/18 with or without other HR types 184 (19.1) 102 (6.5) 0.3 (0.2–0.4) 0.3 (0.2–0.5)
HPV 16/18 alone 80 (8.3) 42 (2.7) 0.3 (0.2–0.5) 0.2 (0.1–0.5)
Non-vaccine HR type(s) with or without HPV 16/18 261 (34.1) 515 (34.1) 1.3 (1.1–1.6) 1.4 (1.0–1.8)
HPV 31/33/45 88 (8.6) 99 (6.4) 0.7 (0.5–1.0) 0.5 (0.3–0.8)
HPV 6/11 61 (6.3) 133 (8.1) 1.3 (0.9–1.8) 1.6 (1.0–2.8)
19–21 years
HPV 16/18 with or without other HR types 136 (17.4) 247 (12.5) 0.7 (0.5–0.9) 0.6 (0.4–0.9)
HPV 16/18 alone 60 (8.0) 113 (5.8) 0.7 (0.5–1.0) 0.5 (0.3–0.9)
Non-vaccine HR type(s) with or without HPV 16/18 216 (35.8) 796 (46.2) 1.8 (1.4–2.2) 1.9 (1.4–2.5)
HPV 31/33/45 67 (8.7) 178 (9.9) 1.2 (0.8–1.6) 0.9 (0.6–1.4)
HPV 6/11 47 (6.0) 157 (8.9) 1.5 (1.0–2.3) 1.7 (0.9–3.0)
22–24 years
HPV 16/18 with or without other HR types 77 (14.8) 112 (18.6) 1.3 (0.9–2.0) 2.0 (1.0–3.8)
HPV 16/18 alone 32 (6.4) 50 (10.2) 1.7 (0.9–3.0) 3.0 (1.2–7.6)
Non-vaccine HR type(s) with or without HPV 16/18 133 (33.8) 230 (41.7) 1.2 (0.9–1.7) 1.1 (0.6–1.9)
HPV 31/33/45 45 (9.3) 59 (8.2) 0 9 (0.5–1.5) 0.8 (0.3–2. 0)
HPV 6/11 22 (4.2) 24 (2.9) 0 7 (0.4–1.3) 0.4 (0.1–1.3)
* Unweighted number givenwithweighted prevalence (%) so that each laboratory contributes equally to the analysis, rather than in proportion to the number of specimens
submitted.
** Adjusted for sexual history, age, venue type, ethnicity and chlamydia positivity.
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Fig. 3. Prevalence of non-vaccine high-risk HPV types by age-group and survey
period.
* Vaccine coverage estimated using published data on national HPV coverage for
each birth-cohort by year. In the 19–21 year old age-group this is calculated sep-
arately for those women who would have been offered the vaccine as part of the
national HPV immunisation programme.
olds in both periods (post-immunisation 34.1% (95% CI 31.4–36.9):
pre-immunisation 34.1% (95% CI 31.1–37.3) p-value =0.998).
The detected prevalence of three HR HPV types against which
cross-protection has been reported from clinical trials, HPV 31,
33 and 45 [11,12] was slightly lower overall post-immunisation,
but with no clear change in the pattern of age-speciﬁc prevalence
(data not shown), nor trend in the adjusted odds ratio by age group
(Table 2).
Multiple infections remained common in this age group, albeit
somewhat reduced in the immunised ages in line with reduced
prevalence of HPV 16/18 (36.8% of HRHPV positive 16–18 year olds
with more than one HR HPV vs. 52 7% in 2008). As in 2008, non-
vaccine HR HPV types were found in over half of the HPV 16/18
positives.
4. Discussion
These ﬁndings are an early indication that the national HPV
immunisation programme is successfully preventing HPV 16/18
infection in sexually active young women in England. There was a
clear change in the pattern of age-speciﬁc HPV 16/18 prevalence
and the prevalence amongst females eligible for immunisation
was considerably lower than previously measured in 2008 prior
to immunisation. Lower HPV16/18 prevalencewas associatedwith
higher immunisation coverage.
These surveillance data show the impact of a high coverage
immunisation programme within the targeted, and slightly older,
population. Without vaccination status, we could not report the
effectiveness amongst those immunised, however thatwould likely
be heavily inﬂuenced by biases in vaccine uptake in these catch-up
cohorts. The ﬁnding of no fall in HPV 16/18 prevalence between
time periods among females above the age of HPV immunisation,
and no change in the age-speciﬁc pattern of non-vaccine HR preva-
lence argues against the HPV 16/18 changes being solely due to
selection biases or time trends and supports their attribution to the
impactof the immunisationprogramme. In fact, theknownchanges
in selection of subjects (e.g. larger proportion of black women and
women attending at Youth clinics) and the change in assay tend
more towards an expectation of higher HPV16/18 prevalence in
the post-immunisation data, if all else was equal.
That we see reductions in VVS-based HPV 16/18 prevalence
estimates is encouraging for expectations that HPV immunisation
will reduce not only cervical infection but also transmission of
infections that may be only transiently present in the lower geni-
tal tract [13]. This therefore favours optimistic assumptions about
herd-protectionof unvaccinatedmales and females. The reductions
we ﬁnd in HPV 16/18 are even greater than those predicted by the
mathematicalmodelling that informed theHPV immunisation pro-
gramme [14,15]. This is possibly because the surveillance sampled
sexually active young women, who have a higher risk of infec-
tion and hence more to gain from vaccination. However, if there
were no selection biases in play, the falls in HPV 16/18 are consis-
tent with close to 100% efﬁcacy among those immunised, or with
lower efﬁcacy (perhaps to be expected in these vaccinated at an
older age) plus some herd-protection effect amongst the unimmu-
nised, and/or higher immunisation coverage than estimated from
the estimated from national data. Conversely, the lower reductions
in some sub-groups (e.g. blackwomenandwomenattendingYouth
clinics) may reﬂect lower uptake of vaccine amongst these sub-
groups than the national average. Among 19–21 year olds in the
post-immunisation survey, even those too old to have been eligi-
ble for immunisation had lower prevalence than 19–21 year olds
in 2008 and lower than contemporary 22–24 year olds which fur-
ther strengthens the evidence for aherd-protection effect, although
more data are needed to conﬁrm the size of this beneﬁt. Given the
levels of coverage and of pre-existing infection in young women of
ages eligible for catch-up immunisation [7], we expect to see larger
reductions in future as herd-protection effects develop and surveil-
lance includesmore girls who have received routine immunisation
at 12 years.
The higher prevalence of non-vaccine HR HPV types in our
post-immunisation survey can be interpreted in several ways. Any
immunisation-associated type-replacement, either due to non-
vaccine types ﬁlling the ecological niches created by removal of
the vaccine types [16,17], or by loss of cross-immunity acquired
through natural infection with HPV 16/18 [18] would likely man-
ifest in this way, at least in the younger vaccinated age-groups.
However, comparison of our pre- and post-immunisation ﬁndings
has some important limitations. The change in assay between the
pre- and post-immunisation surveys was advantageous in terms
of affordability and sustainability of testing for our surveillance.
Cuschieri et al. have shown the potential importance of the effect
of changingassays [19] and thehigherdetection rateofnon-vaccine
HR types found for our post-immunisation assay suggests this has
contributed to the higher prevalence of non-vaccine types post-
immunisation across all ages. In addition, such broad-spectrum
assays, can potentially miss types present in much lower con-
centrations than others, when multiple HPV types are present, as
they commonly are in sexually active young women [7,20–23]
hence non-vaccine type HPV infection may have been under-
estimated in the pre-immunisation survey due to “masking” by
co-infection with HPV 16/18 [24,21]. There may also have been
temporal changes in the prevalence of some or all non-vaccine
types (unrelated to immunisation) between 2008 and 2010–2012.
The reduction in the prevalence of HPV 31, 33 and 45, against the
backdropof increasednon-vaccineHR-HPV is consistentwith some
cross-protective efﬁcacy against these types. It will be interesting
to see whether the change in age-speciﬁc pattern that we have
seen for HPV16/18 emerges for these types in subsequent analy-
ses.
The use of a convenience source of residual genital speci-
mens from youngwomen undergoing chlamydia screening around
England allows a large sample to assess the early impact of the HPV
immunisation programme.Women screened for chlamydia tend to
be at higher risk of chlamydia infection than the general population
[25] andmay therefore be at increased risk of HPV infection, which
likely increases power to detect changes, but limits representative-
ness of the general populationwith regard to risk ofHPVanduptake
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of HPV immunisation. In 2011, an estimated 41% of females aged
16–24 years were screened for chlamydia (assuming one test per
person). This was an increase from approximately 15% in 2008/09.
It is possible, therefore, that the population from which our spec-
imens were drawn had changed somewhat between 2008 and
2010–2012. There was no evidence of a change in reported sexual
behaviour. However, missing data on sexual behaviour increased,
likely associated with the large increase in testing in venues where
this was not asked, and this limited our ability to track shifts in the
risk proﬁle of this specimen source.
Studies from other countries have shown similar ﬁndings since
have introduction of HPV immunisation programmes using the
quadrivalent vaccine. Tabrizi et al. [26] compared a survey of 202
women aged 18–24 years old in 2005–2007 to a similar survey of
404 women from 2010 to 2011 in Australia, with estimated cov-
erage 86%, and showed a substantial decrease (28.7% to 6.7%) in
the vaccine-targeted genotypes (16/18/6/11) as well as a slightly
lower prevalence of non-vaccine oncogenic types. Markowitz et al.
[27] have analysed data from the National Health and Nutrition
Examination Surveys in the United States. Amongst women aged
14–19 years, the prevalence of the HPV vaccine-types (16/18/6/11)
decreased from 11.5% in 1363 unvaccinated women in 2003–2006
to 5.1% in 740women in 2007–2010with an estimated vaccination
coverage of 34% for one dose or more.
This surveillance considers the impact of the immunisation pro-
gramme in England. Surveillance subjects and methods elsewhere
in the UK are different and will offer complementary evidence
regarding the impact and effectiveness of the UK immunisation
programme. In England, this surveillance will continue in order to
determine the extent of herd- protection and of cross-protection
and any type-replacement. To address these remaining questions
future analysis will include larger numbers of surveillance spec-
imens, more time since immunisation, more sampling from the
birth-cohortswith high coverage of routine immunisation and vac-
cine effectiveness will be estimated once immunisation status has
been obtained for some subjects.
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